Community
Advertising Opportunities
Biotechnology Europe Programs
Biotechnology Europe Community
Feedback
Contact
Biotechnology Europe Advantages
Advertising Opportunities on Biotechnology Europe
Sponsorship Opportunities on Biotechnology Europe
Post a Job on Biotechnology Europe
Post a Company Profile on Biotechnology Europe
Post a News on Biotechnology Europe
Post an Event on Biotechnology Europe
Post a Product on Biotechnology Europe
Post a Publication on Biotechnology Europe
Terms of Business
Imprint
Privacy Policy
FAQ
Subscribe Newsletter
03.12.2008 Conclusion of a joint research agreement between Chiome and Chugai: Innovation in the research and development of therapeutic antibodies by means of the revolutionary "ADLib® System" monoclonal antibody identification technology
26.11.2008 Anti-malignancy agent / anti-VEGF humanised monoclonal antibody, Avastin® Application for Approval of Additional Indication of NSCLC
30.07.2008 FDA Advisory Committee Votes in Favor to Recommend Approval of Actemra®, a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, for Rheumatoid Arthritis
16.06.2008 Data from Overseas Phase III Trial (RADIATE and AMBITION) Demonstrates Efficacy of "Actemra®," a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, in Rheumatoid Arthritis Patients
16.04.2008 Actemra®, a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody Obtained Approval for Indications of Rheumatoid Arthritis, Polyarticular-Course Juvenile Idiopathic Arthritis and Systemic-Onset Juvenile Idiopathic Arthritis
02.04.2008 Reinforcement of Structure for the European Sales Bases
29.02.2008 Anti-Cancer Agent Herceptin® Obtained Approval for a New Indication for Adjuvant Therapy in Breast Cancer that Overexpresses HER2
29.02.2008 Combination Therapy of Anti-Cancer Agents, Xeloda®, Elplat® and Avastin®, and Monotherapy of Xeloda® filed for Advanced or Recurrent Colorectal Cancer
26.11.2007 Sativex® Commences US Phase II/III Clinical Trial in Cancer Pain
